Combined treatment with a transforming growth factor beta inhibitor (1D11) and bortezomib improves bone architecture in a mouse model of myeloma-induced bone disease-Reference-Cited by-同舟云学术

Combined treatment with a transforming growth factor beta inhibitor (1D11) and bortezomib improves bone architecture in a mouse model of myeloma-induced bone disease

Published:2016-10 Issue: Volume:91 Page:81-91
ISSN:8756-3282
Container-title:Bone
language:en
Short-container-title:Bone

Author:

Nyman Jeffry S.,Merkel Alyssa R.,Uppuganti Sasidhar,Nayak Bijaya,Rowland Barbara,Makowski Alexander J.,Oyajobi Babatunde O.,Sterling Julie A.

Funder

NIH

Publisher

Elsevier BV

Subject

Histology,Physiology,Endocrinology, Diabetes and Metabolism

Reference38 articles.

1. Bone health in cancer patients: ESMO Clinical Practice Guidelines;Coleman;Ann Oncol,2014

2. Pathologic fractures correlate with reduced survival in patients with malignant bone disease;Saad;Cancer,2007

3. A murine model of human myeloma bone disease;Garrett;Bone,1997

4. Management of bone disease in multiple myeloma;Terpos;Expert. Rev. Hematol.,2014

5. Myeloma bone disease: Pathophysiology and management;Silbermann;J. Bone Oncol.,2013

Cited by 45 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Phenolic acids prevent sex-steroid deficiency-induced bone loss and bone marrow adipogenesis in mice;The Journal of Nutritional Biochemistry;2024-05

2. Immune checkpoint inhibitors in bone metastasis: Clinical challenges, toxicities, and mechanisms;Journal of Bone Oncology;2023-12

3. The use of bone-modifying agents in multiple myeloma;Blood Reviews;2023-01

4. Preventing osteolytic lesions and osteomyelitis in multiple myeloma;Journal of Bone Oncology;2022-12

5. The role of the bone microenvironment in regulating myeloma residual disease and treatment;Frontiers in Oncology;2022-08-22